Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Eligible age
18+ yrs
Accepts
Men
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been found to have abnormalities in DNA repair. The purpose of this research is to study the role of a DNA repair pathway in prostate cancer, specifically in response to administration of radium-223, an FDA-approved drug known to cause DNA damage to cancerous cells. Understanding how defects in the DNA repair pathway affects radium-223 treatment of prostate, may help doctors help plan effective treatment in future patients.
Sponsor: University of Washington
You may qualify if…
- ✓ Patient must be \>= 18 years of age
- ✓ Patient must have histopathologic diagnosis of prostate cancer
- ✓ Patient must have castration-resistant prostate cancer
- ✓ Patient must have radiographic evidence of bone metastasis
- ✓ Patients must be symptomatic from prostate cancer
- ✓ Patient must have plans to undergo treatment with radium-223
- ✓ Patient must have a PSA level \>= 10 ng/mL
- ✓ Patient must have castrate testosterone levels demonstrated within the last 3 months prior to screening
You may not qualify if…
- ✕ Patient must not have visceral metastasis
- ✕ Patients on regimens of radium-223 in combination with other antineoplastic agents are excluded
- ✕ \* Bone-targeted only therapy (e.g. denosumab or zoledronic acid) will be allowed
- ✕ Patients who have received prior radium-223
- ✕ Patients who have received prior platinum containing chemotherapy
- ✕ Absolute neutrophil count (ANC) \< 1.5 x 10\^9/L
- ✕ Hemoglobin (HB) \< 9 g/dL
- ✕ Platelets (PLT) \< 100 x 10\^9/L
Where it's recruiting
Source: ClinicalTrials.gov · NCT04489719 · last updated 2026-10-22